Abstract
The thyroid hormone triiodothyronine (T3) has been used both to augment and accelerate the clinical effects of antidepressants, particularly the tricyclics. More recent work indicates that it may have similar actions with regard to the SSRIs. Two main mechanisms have been put forward to explain its antidepressant actions, (a) an action at the nuclear level involving stimulation of gene transcription, (b) an action at the cell membrane level involving potentiation of neurotransmission. In particular, there is considerable evidence for potentiation by T3 of the actions of the neurotransmitter 5- HT or serotonin. This evidence, which is mainly based on in vivo microdialysis studies, is reviewed, and evidence based on human and animal neuroendocrine studies considered. The effects of T3, alone and together with the SSRI fluoxetine, on mRNA levels for the 5-HT1A and 5-HT1B autoreceptors, which mediate serotonergic neurotransmission by feedback actions at the levels of cell firing(somatodendritic 5-HT1A autoreceptors) and neurotransmitter release (nerve terminal 5- HT1B autoreceptors) were also determined. Administration of a combination of fluoxetine and T3 induced reductions in the transcription of these autoreceptors, which may explain the clinical potentiating effects of this combination, and thus link the nuclear and neurotransmitter hypotheses of T3 action.
Keywords: Triiodothyronine, serotonin, depression, antidepressant, microdiaysis, mRNA, fluoxetine, autoreceptor
Current Drug Targets
Title: Basic Mechanisms of Augmentation of Antidepressant Effects with Thyroid Hormone
Volume: 7 Issue: 2
Author(s): Tsuri Lifschytz, Ronen Segman, Galit Shalom, Bernard Lerer, Eitan Gur, Tanya Golzer and Michael E. Newman
Affiliation:
Keywords: Triiodothyronine, serotonin, depression, antidepressant, microdiaysis, mRNA, fluoxetine, autoreceptor
Abstract: The thyroid hormone triiodothyronine (T3) has been used both to augment and accelerate the clinical effects of antidepressants, particularly the tricyclics. More recent work indicates that it may have similar actions with regard to the SSRIs. Two main mechanisms have been put forward to explain its antidepressant actions, (a) an action at the nuclear level involving stimulation of gene transcription, (b) an action at the cell membrane level involving potentiation of neurotransmission. In particular, there is considerable evidence for potentiation by T3 of the actions of the neurotransmitter 5- HT or serotonin. This evidence, which is mainly based on in vivo microdialysis studies, is reviewed, and evidence based on human and animal neuroendocrine studies considered. The effects of T3, alone and together with the SSRI fluoxetine, on mRNA levels for the 5-HT1A and 5-HT1B autoreceptors, which mediate serotonergic neurotransmission by feedback actions at the levels of cell firing(somatodendritic 5-HT1A autoreceptors) and neurotransmitter release (nerve terminal 5- HT1B autoreceptors) were also determined. Administration of a combination of fluoxetine and T3 induced reductions in the transcription of these autoreceptors, which may explain the clinical potentiating effects of this combination, and thus link the nuclear and neurotransmitter hypotheses of T3 action.
Export Options
About this article
Cite this article as:
Lifschytz Tsuri, Segman Ronen, Shalom Galit, Lerer Bernard, Gur Eitan, Golzer Tanya and Newman E. Michael, Basic Mechanisms of Augmentation of Antidepressant Effects with Thyroid Hormone, Current Drug Targets 2006; 7 (2) . https://dx.doi.org/10.2174/138945006775515482
DOI https://dx.doi.org/10.2174/138945006775515482 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
IBD Modern Concepts, Nano Drug Delivery and Patents: An Update
Recent Patents on Nanomedicine Molecular Phenotype of CXCL12β 3UTR G801A Polymorphism (rs1801157) Associated to HIV-1 Disease Progression
Current HIV Research Comparative Proteomics Analysis of Developing Seed of a Pre-Harvest Seed Deterioration Resistant Soybean Cultivar Under High Temperature and Humidity Stress
Current Proteomics The Importance of the Adenosine A2A Receptor-Dopamine D2 Receptor Interaction in Drug Addiction
Current Medicinal Chemistry Editorial [The Drinking Culture of Fraternity and Sorority Members]
Current Drug Abuse Reviews Mitochondrial Membrane Lipids in Life and Death and their Molecular Modulation by Diet: Tuning the Furnace
Current Drug Targets Irritable Bowel Syndrome: A Clinical Review
Current Rheumatology Reviews Apoptosis Induction by Thalidomide: Critical for Limb Teratogenicity but Therapeutic Potential in Idiopathic Pulmonary Fibrosis?
Current Molecular Pharmacology N-Dealkylation of Arylpiperazine Derivatives: Disposition and Metabolism of the 1-Aryl-Piperazines Formed
Current Drug Metabolism Chinese Herbs and Herbal Extracts for Neuroprotection of Dopaminergic Neurons and Potential Therapeutic Treatment of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Spectroscopic and Functional Characterization of Human β-Synuclein
Protein & Peptide Letters Neurofibrillary Tangles and Senile Plaques in Alzheimers Brains are Associated with Reduced Capillary Expression of Vascular Endothelial Growth Factor and Endothelial Nitric Oxide Synthase
Current Neurovascular Research Role of Environmental Factors in Cocaine Addiction
Current Pharmaceutical Design Diabetes and Chronic Heart Failure: From Diabetic Cardiomyopathy to Therapeutic Approach
Endocrine, Metabolic & Immune Disorders - Drug Targets Polyphenols and Depression: from Chemistry to Medicine
Current Pharmaceutical Biotechnology Drug Discovery in Ovarian Cancer
Recent Patents on Anti-Cancer Drug Discovery Animal Models of Ejaculatory Behavior
Current Pharmaceutical Design Alcohol and Smoking Mediated Oxidative Stress in Organ Toxicities: Role of Cytochrome P450 Systems
Mini-Reviews in Organic Chemistry Outcomes in Older Versus Younger Patients Over 96 Weeks in HIV-1– Infected Patients Treated with Rilpivirine or Efavirenz in ECHO and THRIVE
Current HIV Research APP-Based Neuroprotective Strategies
Current Alzheimer Research